RaySearch is down 50% from its peak. The market still prices it as a treatment planning tool. But the company is quietly becoming the operating system for radiation oncology, and if the platform transition plays out, this could be a multi-bagger from here.

New deep-dive out now. Happy reading, and happy Easter!